Research Paper Volume 8, Issue 2 pp 345—365

p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function

class="figure-viewer-img"

Figure 6. Gene expression profiling analysis. (A) Heatmap for comparison between p63+ and p63 DLBCL patients (false discovery rate < 0.15). (B) Heatmap for comparison between p63+ and p63 DLBCL patients with MUT-TP53 (false discovery rate < 0.05, fold change >1.68). (C) Heatmap for comparison between p63+ versus p63 patients with ABC-DLBCL and WT-TP53 (false discovery rate < 0.20). (D) Heatmap for comparison between p63+ versus p63 patients with GCB-DLBCL (false discovery rate < 0.05). (E) Heatmap for comparison between p63+ and p63 DLBCL patients with MUT-p53 overexpression (false discovery rate < 0.15). (F) Heatmap for comparison between p63+ and p63 DLBCL patients with no or low (< 20%) expression levels of MUT-p53 (false discovery rate < 0.10). (G) Heatmap for comparison between WT-p53+ (≥ 20%) and WT-p53 (< 20%) DLBCL patients with p63 expression (false discovery rate < 0.30). (H) Heatmap for comparison between MUT-p53+ (≥ 20%) and MUT-p53 (< 20%) DLBCL patients with p63 expression (false discovery rate < 0.20).